利拉鲁肽治疗多囊卵巢综合征合并2型糖尿病患者的初步临床研究

摘要

目的 探讨利拉鲁肽与二甲双胍对多囊卵巢综合征(PCOS)合并2型糖尿病(T2DM)患者代谢和内分泌参数的影响.方法 将62例PCOS合并T2DM患者随机分为两组.分别给予利拉鲁肽(1.2~1.8 mg/d)和二甲双胍0.5 g/d,治疗12周.评估治疗前后各项代谢指标和性激素水平的变化.结果 与治疗前相比,治疗后两组血糖(FPG)、餐后2小时血糖(2 hPG)、糖化血红蛋白(HbA1 c)、体质量指数(BMI)及胰岛素抵抗指数(HOMA-IR)均改善(P0.05).结论利拉鲁肽可改善PCOS合并T2DM患者的高血糖和胰岛素抵抗,并有助于改善高雄激素血症.%Objective To investigate the efficacy of liraglutide and metformin on metabolic and endocrine parameters in polycystic ovary syndrome (PCOS)patients with type 2 diabetes mellitus (T2DM).Methods A total of 62 PCOS patients with T2DM were randomly divided into two groups,and liraglutide (1.2-1.8 mg/d )or metformin (0.5 g/d)were used for 12 weeks,respectively.Metabolic parameters and sexual hormones were evaluated before and after treatment.Results After 12 weeks'treatment,the levels of FPG,2 hPG,HbA1 c,BMI and HOMA-IR were significantly improved in both groups (P 0.05).Conclusion Liraglutide can improve hyperglycemia and insulin resistance in PCOS patients with T2DM,and can also be helpful in improving hyperandrogenism.